Logo image
Back
Hospital Readmission in Left Ventricular Assist Device (LVAD) Patients Compared to Patients Receiving Intravenous Inotropic Therapy
Journal article   Peer reviewed

Hospital Readmission in Left Ventricular Assist Device (LVAD) Patients Compared to Patients Receiving Intravenous Inotropic Therapy

J. Whittier, P. Pirlamarla, J. Patel, S. Feitell, E. Gongora, T. Rowe, S. Hankins and H.J. Eisen
The Journal of heart and lung transplantation, v 32(4), pp S24-S24
Apr 2013
DOI: https://doi.org/10.1016/j.healun.2013.01.042
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Patients with advanced heart failure (HF) have improved survival with LVADs. Some patients receive intravenous, continuous milrinone as support prior to transplant. Hospital readmission are frequent events in patients with HF. There is little data on hospital readmissions with LVAD compared to milrinone. The aim of our study was to compare the readmission and HF exacerbation rates for milrinone patients compared to LVAD patients. Readmission rates were compared for patients receiving milrinone to patients with LVADs at a single-center. The comparison studied readmission and HF exacerbation rates between 2007 and 2011 at 1,3,6 and 9 month and 1 year intervals. A total of 64 patients were evaluated. Hospital readmission rates for LVAD and milrinone patients were compared for both all-cause diagnoses and specifically for HF. The mean number of all-cause hospitalizations for LVAD patients was 3.22 compared to 5.70 for milrinone patients at one year (p=0.0074). The mean number of HF exacerbations for LVAD patients was 0.84 compared to 2.20 for milrinone patients at one year (p= 0.0039). These findings were also observed at 1, 3, 6 and 9 month intervals. LVAD patients had fewer hospital readmissions and HF exacerbations compared to milrinone patients, suggesting a potential advantage for earlier LVAD implantation in patients with advanced HF Time After DischargeMilrinone HF ExacerbationsVAD HF ExacerbationsP ValueMilrinone RehospitalizationsVAD RehospitalizationsP-Value1 month0.58 + 0.12 (n=31)0.03 + 0.03 (n=33)<0.00010.71 + 0.16 (n=31)0.06 + 0.04 (n=33)<0.00013 month1.21 + 0.21 (n=24)0.21 + 0.08 (n=33)<0.00011.88 + 0.26 (n=24)0.88 + 0.17 (n=33)0.00186 month2.06 + 0.35 (n=16)0.33 + 0.10 (n=33)<0.00013.81 + 0.29 (n=16)1.88 + 0.29 (n=33)0.00139 month2.10 + 0.62 (n=10)0.50 + 0.13 (n=33)0.00034.80 + 0.90 (n=10)2.53 + 0.39 (n=32)0.01121 year2.20 + 0.59 (n=10)0.84 + 0.17 (n=32)0.00395.70 + 0.99 (n=10)3.22 + 0.39 (n=32)0.0074

Metrics

11 Record Views
1 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Respiratory System
Surgery
Transplantation
Logo image